Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Radcliffe Department of Medicine's Professor Adam Mead is leading PROMise, a new clinical trial offering a novel treatment option for patients with a type of blood cancer called myelofibrosis.

Each year in the UK, over 300 patients are diagnosed with myelofibrosis,  a blood cancer associated with debilitating symptoms including extreme fatigue, pain, weakness and shortness of breath. Around 10-20% of patients go on to develop acute myeloid leukaemia, with median survival from the time of diagnosis just 2 years for patients with high-risk disease.

Stem cell transplant are the only cure for myelofibrosis, but this is only suitable for a small minority of younger patients who don't have other conditions as well. Instead, the standard NHS care for the illness is treatment with a drug called ruxolitnib, but many patients do not respond to this treatment.

Professor Mead said "The PROMise study is a really exciting study that has just opened in the UK and will be opening across 15 centres. This is introducing a new treatment called PLX2853, in combination with ruxolitininb, for patients with MF (myelofibrosis)."

Read the full story on the Radcliffe Department of Medicine website.

Similar stories

New Studentship honours Enzo Cerundolo

A new Studentship has been announced in memory of the late MRC HIU Director and MRC WIMM Group Leader.

2022 RDM Graduate Prize Winners

This year's RDM winners are Edward Jenkins, Antje Rottner, and Akshay Shah.

Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing

The biotechnology company builds upon research conducted by Professor Jim Hughes and Prof. James Davies at the MRC Weatherall Institute of Molecular Medicine, and combines 3D genome technology and machine learning to decode the dark matter of the human genome.

KJ Patel appointed new Chief Scientist of CRUK

Alongside his new role at Cancer Research UK, Prof. Patel will continue as the Director of both the MRC Weatherall Institute for Molecular Medicine (MRC WIMM) and the MRC Molecular Haematology Unit (MRC MHU).

September is Childhood Cancer Awareness Month

September is Childhood Cancer Awareness Month, where our Childhood Leukaemia research group have taken action to help raise awareness for this cause.